


# PRODUCT INFORMATION



## Alofanib

Item No. 31754

**CAS Registry No.:** 1612888-66-0  
**Formal Name:** 3-[[[4-methyl-2-nitro-5-(3-pyridinyl)phenyl]amino]sulfonyl]-benzoic acid  
**Synonym:** RPT835  
**MF:** C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>6</sub>S  
**FW:** 413.4  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Alofanib is supplied as a crystalline solid. A stock solution may be made by dissolving the alofanib in the solvent of choice, which should be purged with an inert gas. Alofanib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of alofanib in these solvents is approximately 30 mg/ml.

Alofanib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, alofanib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Alofanib has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Alofanib is an allosteric inhibitor of FGFR2.<sup>1,2</sup> It inhibits FGF2-induced phosphorylation of FGFR substrate 2 (FRS2α) in KATO III gastric carcinoma cells (IC<sub>50</sub> = <10 nM).<sup>2</sup> Alofanib inhibits the growth of SKOV3 ovarian and Hs 578T breast cancer cells (GI<sub>50</sub>s = 370 and 210 nM, respectively). It inhibits proliferation of human umbilical vein endothelial cells (HUVECs) induced by basic FGF (bFGF; IC<sub>50</sub> = 11 nM) and tube formation of SVEC4-10 endothelial cells when used at a concentration of 50 nM.<sup>1</sup> It also inhibits migration of SVEC4-10 cells in a wound healing assay. Alofanib (50 mg/kg) decreases the number of microvessels in tumor tissue by 50% in a SKOV3 ovarian serous carcinoma mouse model. It reduces tumor growth in mouse xenograft models when administered at a dose of 30 mg/kg per day, and the degree of tumor volume reduction positively correlates with the expression level of FGFR2.<sup>2</sup>

### References

1. Khochenkov, D.A., Solomko, E.S., Peretolchina, N.M., *et al.* Antiangiogenic activity of alofanib, an allosteric inhibitor of fibroblast growth factor receptor 2. *Bull. Exp. Biol. Med.* **160**(1), 84-87 (2015).
2. Tsimafeyeu, I., Ludes-Meyers, J., Stepanova, E., *et al.* Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. *Eur. J. Cancer* **61**, 20-28 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM